InvestSMART

6K Additive, Inc (ASX:6KA)

ALERT: Price-sensitive ASX Announcement for 6KA
Current share price for 6KA : $0.760 -0.018 (-2.25%)+
Announcement
Release
28 Apr 2026 9:17AM
Price at Release
$0.778
Full Release
download
Summary
Island Pharmaceuticals Limited is working on addressing urgent viral diseases and biosecurity threats through the development of ISLA-101 for dengue fever and Galidesivir, an antiviral molecule effective against multiple RNA viruses. As of March 2026, the company reported cash holdings of $14.18 million and a net operational cash usage of $1.3 million. Payments to related parties amounted to $139,000, which included executive and director fees.
Key Points
  • Island Pharmaceuticals Limited focuses on urgent viral diseases and biosecurity threats.
  • They are developing ISLA-101 and Galidesivir as part of their strategy.
  • ISLA-101 is used for dengue fever prevention and treatment.
  • Galidesivir is an antiviral molecule targeting multiple RNA viruses.
  • The company held $14.18 million in cash as of March 2026.
  • Net cash used in operations was $1.3 million for the quarter.
  • Payments to related parties totaled $139,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.